<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914212</url>
  </required_header>
  <id_info>
    <org_study_id>0000-103</org_study_id>
    <secondary_id>103</secondary_id>
    <secondary_id>2009_597</secondary_id>
    <nct_id>NCT00914212</nct_id>
  </id_info>
  <brief_title>A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)</brief_title>
  <official_title>A Functional Magnetic Resonance Imaging (fMRI) Study of the Reproducibility and the Effect of Sibutramine During Fasted and Fed Conditions in Healthy Overweight and Obese Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether BOLD-fMRI can be used to probe hunger and satiety states in
      healthy overweight or obese men and also whether fasted/fed fMRI signals can be modulated by
      sibutramine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average percent signal change of the top 20% of activated voxels (AvgPSC20) during the fasted condition over six primary brain regions of interest (ROI)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraclass coefficient of correlation of the AvgPSC20 assessed during the fed and fasted conditions over the six ROIs</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional cerebral blood flow (rCBF) during the fasted condition with placebo or sibutramine in the six ROIs</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AvgPSC20 in the fed condition with placebo or sibutramine in the six ROIs</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in PSC20 during fasted and fed conditions with placebo or sibutramine in the six ROIs</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rCBF during the fed condition with placebo or sibutramine in the six ROIs</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in rCBF during fasted and fed conditions with placebo or sibutramine in the six ROIs</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test-retest reliability of rCBF in the six ROIs during the fasted and fed states in men receiving placebo</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sibutramine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose placebo to sibutramine in two of three treatment periods.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: sibutramine</intervention_name>
    <description>Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>sibutramine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a male between 18 and 45 years of age

          -  Subject has a body mass index (BMI) between 28 and 35 kg/m^2

          -  Subject does not weigh more than 140 kg (309 lbs) at the screening visit

          -  Subject is right-handed

          -  Subject is a non-smoker

          -  Subject is in generally good health

          -  Subject has normal or corrected to normal vision

        Exclusion Criteria:

          -  Subject works a night shift within 3 days of each treatment visit

          -  Subject has permanent cosmetic or metallic objects in his body

          -  Subject has attention deficit hyperactivity disorder (ADHD)

          -  Subject has or had sleep apnea

          -  Subject has a history of neurological disorders

          -  Subject has a history of any clinically significant disease or condition

          -  Subject is vegan or vegetarian

          -  Subject has a history of eating disorders

          -  Subject has had previous bariatric surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>October 9, 2015</last_update_submitted>
  <last_update_submitted_qc>October 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sibutramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

